Abstract
Five tumor markers (CEA, Ferritin, CA-50, TPA and SCC) were assayed in 54 patients with ear, nose and throat (ENT) cancers in early and advanced stages. The specificity of these markers always exceeded 95%. Their sensitivity ranged from 13 to 43%, and reached 72% as a combination of all five markers. No distinction was found between early and advanced stage of illness. These markers seem to have no distinct function in ENT oncological diagnosis and follow-up because objective data is easily available even in early tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
